Aptinyx to Participate in Upcoming Conferences
April 27 2021 - 7:57AM
Business Wire
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical
company developing transformative therapies for the treatment of
brain and nervous system disorders, today announced that the
Company will be participating in two upcoming conferences:
- 4th Annual Neuroscience Innovation Forum – Norbert Riedel,
Ph.D., chief executive officer, will participate in the Pain &
Addiction Panel discussion at 11:30 a.m. ET on April 29, 2021;
and
- 7th Annual Truist Securities Life Sciences Summit – Aptinyx
management will participate in one-on-one meetings with investors
throughout the conference on May 4 – 5, 2021.
About Aptinyx
Aptinyx Inc. is a clinical-stage biopharmaceutical company
focused on the discovery, development, and commercialization of
proprietary synthetic small molecules for the treatment of brain
and nervous system disorders. Aptinyx has a platform for discovery
of novel compounds that work through a unique mechanism to
modulate—rather than block or over-activate—NMDA receptors and
enhance synaptic plasticity, the foundation of neural cell
communication. The company has three product candidates in clinical
development in central nervous system indications, including
chronic pain, post-traumatic stress disorder, and cognitive
impairment. Aptinyx is also advancing additional compounds from its
proprietary discovery platform, which continues to generate a rich
and diverse pipeline of small-molecule NMDA receptor modulators
with the potential to treat an array of neurologic disorders. For
more information, visit www.aptinyx.com.
Source: Aptinyx Inc.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210427005080/en/
Investor and Media Contact: Nick Smith Aptinyx Inc.
ir@aptinyx.com or corporate@aptinyx.com 847-871-0377
Aptinyx (NASDAQ:APTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aptinyx (NASDAQ:APTX)
Historical Stock Chart
From Apr 2023 to Apr 2024